Quantcast

Latest Mylan Inc. Stories

2014-05-29 08:29:06

PITTSBURGH, May 29, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone(®) Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prophylaxis of Plasmodium falciparum malaria and the treatment of...

2014-05-28 12:30:09

PITTSBURGH, May 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the INVEST Pennsylvania Equity Conference on Thursday, May 29, 2014, in Pittsburgh. The presentation is scheduled to begin at 9:25 a.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://mylan.com/investors. An...

2014-05-20 08:29:12

LONDON, May 20, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Generic Drugs Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/generic_drugs/global_generic_drugs_market_2014_2018.htmlTechNavio's analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is...

2014-05-15 08:31:31

PITTSBURGH, May 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today commented on the ruling by the U.S. District Court for the District of Columbia against Teva in their suit against the U.S. Food and Drug Administration (FDA), which denied Teva's motion to block FDA from approving generic versions of Copaxone® and dismissed the case for lack of jurisdiction. Mylan had intervened in this suit in support of FDA. http://photos.prnewswire.com/prnvar/20140423/77793 Mylan CEO...

2014-05-14 08:30:09

PITTSBURGH, May 14, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Company's Zyprexa Zydis(®) Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of schizophrenia or the acute treatment of manic or...

2014-05-09 12:26:05

PITTSBURGH, May 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the UBS Global Healthcare Conference on Tuesday, May 20, 2014, in New York. The presentation is scheduled to begin at 10:30 a.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://mylan.com/investors. An archived...

2014-05-09 08:26:49

PITTSBURGH, May 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the BofA Merrill Lynch 2014 Health Care Conference on Wednesday, May 14, 2014, in Las Vegas. The presentation is scheduled to begin at 11:20 a.m. PT. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at...

2014-05-01 08:34:57

Reaffirms 2014 Adjusted Diluted EPS Guidance Range of $3.25 - $3.60 PITTSBURGH, May 1, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31, 2014. Financial Highlights -- Adjusted diluted EPS of $0.66 for the three months ended March 31, 2014 compared to $0.62 for the same prior year period, an increase of 6% -- Total revenues of $1.72 billion for the three months ended March 31, 2014 compared to...

2014-04-25 20:21:31

Mylan Seeks to Confirm Shared 180-Day Exclusivity PITTSBURGH, April 25, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has filed suit against the U.S. Food and Drug Administration (FDA), challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib Capsules, the generic version of Pfizer's Celebrex(®). FDA issued a decision holding that eligibility for 180 days of exclusivity is only available to an applicant who first filed a...

2014-04-18 20:21:09

PITTSBURGH, April 18, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone(®) pending the Supreme Court's decision on Teva's appeal. This is the second time that the Chief Justice has denied Teva's request for such an injunction. In March, the Supreme Court granted Teva's petition for certiorari seeking clarification of...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'